Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1670129

registered interest
date	14/11/2023
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Electric Vehicles: Charging Points
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what steps they are taking to encourage District Network Operators to make the process of grid connection and upgrade easier for fleets installing EV charging infrastructure; and whether they have any plans to expand Project Rapid to focus on additional transport hubs such as airports, shared depots and truck rest areas.
tabling member printed	Baroness Randerson
uin	HL309
answer	answer is ministerial correction date of answer 28/11/2023 answer text <p>As set out in the Powering Up Britain Energy Security Plan, and subsequent Prime Minister’s speech on net zero on 20 September, Government is committed to reducing grid connection timescales for EV charging and other projects. The forthcoming Government and Ofgem Connections Action Plan will set out action to accelerate grid connection timescales for all customers including demand projects, such as EV chargepoint infrastructure. In addition, the Plan for Drivers published in October 2023, committed to a review of grid connections, specifically focused on EV infrastructure.</p><p> </p><p>The Government has no plans to extend the scope of the Rapid Charging Fund beyond the strategic road network. The Government is planning to publish a consultation on the Rapid Charging Fund shortly.</p> answering member printed Lord Davies of Gower question first answered 28/11/2023 15:02:52 answering member 4499 label Biography information for Lord Davies of Gower
tabling member	4230 label Biography information for Baroness Randerson

1670130

registered interest
date	14/11/2023
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Electric Vehicles: Charging Points
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what plans they have to address regional disparities in chargepoint provision per capita in each locality.
tabling member printed	Baroness Randerson
uin	HL310
answer	answer is ministerial correction date of answer 27/11/2023 answer text <p>Government and industry have supported the installation of 49,220 publicly available charging devices as of 1 October 2023. This includes more than 8,900 50kW or above charging devices.</p><p> </p><p>The £381 million Local EV Infrastructure (LEVI) Fund supports local authorities in England to work with industry and transform the availability of charging for drivers without off-street parking. This will deliver tens of thousands of local chargepoints, ensuring the transition to electric vehicles takes place in every part of the country. Local authority funding was allocated by evaluating need and progress in relation to chargepoint rollout, helping to address existing disparities with infrastructure provision.</p><p> </p> answering member printed Lord Davies of Gower question first answered 27/11/2023 15:01:14 answering member 4499 label Biography information for Lord Davies of Gower
tabling member	4230 label Biography information for Baroness Randerson

1670131

registered interest
date	14/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hepatitis: Disease Control
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the Written Answer by Lord Markham on 28 March (HL6760), what steps they have taken in support of preparation for the maintenance phase of hepatitis elimination.
tabling member printed	Baroness Randerson
uin	HL311
answer	answer is ministerial correction date of answer 28/11/2023 answer text <p>The UK Health Security Agency (UKHSA) supports and monitors progress towards the World Health Organisation goal of eliminating hepatitis C virus (HCV) as a major public health threat by 2030. As part of disease surveillance, UKHSA monitors HCV prevention, testing, diagnoses and treatment in England.</p><p>Work to support the elimination maintenance phase is currently being developed with multiple stakeholders including NHS England Specialised Commissioning, integrated care boards, the Department, and UKHSA.</p> answering member printed Lord Markham question first answered 28/11/2023 17:25:58 answering member 4948 label Biography information for Lord Markham
tabling member	4230 label Biography information for Baroness Randerson

1670132

registered interest
date	14/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the Written Answer by Lord Markham on 28 March (HL6761), what assessment they have made of the opportunities of utilising peer-to-peer support workers and volunteers with lived experience in the delivery of inclusion health initiatives.
tabling member printed	Baroness Randerson
uin	HL312
answer	answer is ministerial correction date of answer 22/11/2023 answer text <p>No assessment has been made.</p> answering member printed Lord Markham question first answered 22/11/2023 12:09:49 answering member 4948 label Biography information for Lord Markham
tabling member	4230 label Biography information for Baroness Randerson

1668111

registered interest
date	07/11/2023
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Roads: Birmingham City Council
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government whether the Commissioners appointed to oversee the responsibilities of Birmingham City Council are intending to accept the negotiated new contract for the maintenance of road services, in time to ensure a handover at the expiration of the current contract on 31 January 2024; and if they do not plan to do so, what steps are the taking to ensure alternative arrangements are made for road maintenance in the city.
tabling member printed	Baroness Randerson
uin	HL65
answer	answer is ministerial correction date of answer 14/11/2023 answer text <p>The Government is currently considering the Business Case for a revised contract for Birmingham Highways Maintenance following the failure of Birmingham's original PFI deal. A decision is expected in due course.</p><p>Highways maintenance is a critical and statutory function for all Local Authorities and the government will continue to support authorities to fulfil this function.</p><p>Commissioners have oversight of strategic financial decision-making at the Council and they will want to be satisfied that the contract achieves value for money for Birmingham residents. They are providing advice and challenge to the council, and are able to make decisions directly, if necessary.</p> answering member printed Baroness Vere of Norbiton question first answered 14/11/2023 17:34:49 answering member 4580 label Biography information for Baroness Vere of Norbiton
tabling member	4230 label Biography information for Baroness Randerson

1668173

registered interest
date	07/11/2023
answering body	Department for Transport
answering dept id	27
answering dept short name	Transport
answering dept sort name	Transport
hansard heading	Electric Vehicles: Licensing
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the Motorcycle Industry Association and Zemo Partnership report Realising the Full Potential of Zero Emission Powered Light Vehicles: A Joint Action Plan for Government and Industry — The Route to Net Zero, published in February 2022, what steps they are taking to reform the licencing regime for powered light vehicles, as set out in action six of that report.
tabling member printed	Baroness Randerson
uin	HL66
answer	answer is ministerial correction date of answer 21/11/2023 answer text <p>The Government is open to discussing ideas for reform of the existing licensing regime for powered light vehicles known as L category vehicles where they do not compromise safety standards. The Government intends to engage with the Motorcycle Industry Association in the coming weeks to discuss and consider how they align with existing work and planning linked to licencing reform.</p><p> </p><p> </p> answering member printed Lord Davies of Gower question first answered 21/11/2023 16:20:28 answering member 4499 label Biography information for Lord Davies of Gower
tabling member	4230 label Biography information for Baroness Randerson

1668174

registered interest
date	07/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diffuse Intrinsic Pontine Glioma: Research
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government how much funding they have allocated for research into the treatment of Diffuse Intrinsic Pontine Glioma brain tumours in children in each of the last 10 years; and to which organisations were those funds allocated.
tabling member printed	Baroness Randerson
uin	HL67
answer	answer is ministerial correction date of answer 13/11/2023 answer text <p>The following table shows eight research studies around Diffuse Intrinsic Pontine Glioma, funded by research funding partners in the charity and public sectors since 2013 which have been supported by the National Institute for Health and Care Research (NIHR):</p><table><tbody><tr><td><p>Study Title</p></td><td><p>Opening Date</p></td><td><p>Closure Date</p></td><td><p>Funders</p></td><td><p>Status</p></td></tr><tr><td><p>Phase I trial of afatinib in paediatric patients with neuroectodermal tumours and rhabdomyosarcoma</p></td><td><p>13/07/2015</p></td><td><p>05/05/2020</p></td><td><p>Boehringer Ingelheim Ltd</p></td><td><p>Closed to Recruitment, Follow Up Complete</p></td></tr><tr><td><p>A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors</p></td><td><p>25/08/2016</p></td><td><p>31/12/2018</p></td><td><p>F. Hoffmann-La Roche Ltd</p></td><td><p>Closed to Recruitment, In Follow Up</p></td></tr><tr><td><p>Biological Medicine for Diffuse Intrinsic Pontine Glioma Eradication (Biomede)</p></td><td><p>14/04/2017</p></td><td><p>29/09/2019</p></td><td><p>Cancer Research UK</p></td><td><p>Closed to Recruitment, In Follow Up</p></td></tr><tr><td><p>Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies</p></td><td><p>14/08/2017</p></td><td><p>22/02/2019</p></td><td><p>Bristol-Myers Squibb International Corporation</p></td><td><p>Closed to Recruitment, In Follow Up</p></td></tr><tr><td><p>A PHASE 2 CLINICAL STUDY OF POMALIDOMIDE (CC-4047) MONOTHERAPY FOR CHILDREN AND YOUNG ADULTS WITH RECURRENT OR PROGRESSIVE PRIMARY BRAIN TUMORS</p></td><td><p>17/10/2017</p></td><td><p>27/09/2018</p></td><td><p>CELGENE CORPORATION</p></td><td><p>Closed to Recruitment, In Follow Up</p></td></tr><tr><td><p>A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling</p></td><td><p>15/02/2023</p></td><td><p>31/01/2025</p></td><td><p>Blueprint Medicines Corporation</p></td><td><p>Suspended</p></td></tr><tr><td><p>***</p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td></tr><tr><td><p>***</p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td></tr></tbody></table><p> </p><p>*** Please note that the 2 commercial studies, due to the commercial sensitivity, cannot be shared more widely or made public.</p><p> </p><p>NIHR provides infrastructure support to studies taking place in the National Health Service. For example, staff, research nurses, local networks and NHS trusts will work across many studies, to varying degrees. As a result, NIHR cannot provide precise information on expenditure.</p><p> </p><p>The NIHR Clinical Research Network supports the delivery of high-quality research across the NHS, community and social care and public health organisations. It does this by meeting the costs of additional staff, facilities, equipment and support services.</p><p> </p><p>In May 2018 the Government announced £40 million for brain tumour research as part of the Tessa Jowell Brain Cancer Mission. The Government is committed to funding high-quality brain cancer research. The £40 million funding remains available.</p> answering member printed Lord Markham grouped question UIN HL70 question first answered 13/11/2023 11:45:36 answering member 4948 label Biography information for Lord Markham
tabling member	4230 label Biography information for Baroness Randerson

1668176

registered interest
date	07/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Brain: Tumours
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the All-Party Parliamentary Group on Brain Tumours report Brain Tumours: Pathway to a Cure — breaking down the barriers, published on 28 February, whether they have accepted recommendation six contained in that report that specific funding should be ring-fenced for research into childhood brain tumours; and if so, what is the timescale for implementation.
tabling member printed	Baroness Randerson
uin	HL68
answer	answer is ministerial correction date of answer 13/11/2023 answer text <p>It is not usual practice to ring-fence research funds for particular topics or conditions. As with other Government funders of health research, the National Institute for Health and Care Research (NIHR) does not allocate funding for specific disease areas. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p><p>The Department welcomes the APPG report, recommendations of which continue to be worked through with the Department of Science, Innovation and Technology, and UK Research and Innovation and the Medical Research Council (MRC), and with the NIHR.</p> answering member printed Lord Markham question first answered 13/11/2023 17:49:10 answering member 4948 label Biography information for Lord Markham
tabling member	4230 label Biography information for Baroness Randerson

1668177

registered interest
date	07/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cancer: Children
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government whether they have any plans to develop a bespoke research strategy for childhood cancers with the worst survival rates, including Diffuse Intrinsic Pontine Glioma; and what steps they are taking to encourage drug development to treat those cancers.
tabling member printed	Baroness Randerson
uin	HL69
answer	answer is ministerial correction date of answer 13/11/2023 answer text <p>The Department invests over £1 billion per year in health research through the National Institute for Health and Care Research (NIHR). The NIHR funds and supports health, public health and social care research that leads to improved outcomes for patients and the public and makes the health and social care system more efficient, effective, and safe. Research evidence is vital for improving treatments and outcomes for people, including childhood cancers.</p><p>The Department does not directly commission research; rather, we invite funding applications for research into any aspect of human health. As with other Government funders of health research, the NIHR does not allocate funding for specific disease areas. The level of research spend in a particular area, is driven by factors including scientific potential and the number and scale of successful funding applications. It is also worth noting that all applications that were fundable in open competition have been funded.</p> answering member printed Lord Markham question first answered 13/11/2023 11:05:34 answering member 4948 label Biography information for Lord Markham
tabling member	4230 label Biography information for Baroness Randerson

1668178

registered interest
date	07/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Brain: Tumours
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what collaborative research they are currently funding in partnership with other countries into childhood brain tumours, including Diffuse Intrinsic Pontine Glioma; and whether this includes funding for access to clinical trials.
tabling member printed	Baroness Randerson
uin	HL70
answer	answer is ministerial correction date of answer 13/11/2023 answer text <p>The following table shows eight research studies around Diffuse Intrinsic Pontine Glioma, funded by research funding partners in the charity and public sectors since 2013 which have been supported by the National Institute for Health and Care Research (NIHR):</p><table><tbody><tr><td><p>Study Title</p></td><td><p>Opening Date</p></td><td><p>Closure Date</p></td><td><p>Funders</p></td><td><p>Status</p></td></tr><tr><td><p>Phase I trial of afatinib in paediatric patients with neuroectodermal tumours and rhabdomyosarcoma</p></td><td><p>13/07/2015</p></td><td><p>05/05/2020</p></td><td><p>Boehringer Ingelheim Ltd</p></td><td><p>Closed to Recruitment, Follow Up Complete</p></td></tr><tr><td><p>A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors</p></td><td><p>25/08/2016</p></td><td><p>31/12/2018</p></td><td><p>F. Hoffmann-La Roche Ltd</p></td><td><p>Closed to Recruitment, In Follow Up</p></td></tr><tr><td><p>Biological Medicine for Diffuse Intrinsic Pontine Glioma Eradication (Biomede)</p></td><td><p>14/04/2017</p></td><td><p>29/09/2019</p></td><td><p>Cancer Research UK</p></td><td><p>Closed to Recruitment, In Follow Up</p></td></tr><tr><td><p>Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination with Ipilimumab in Pediatric Subjects with High Grade Primary CNS Malignancies</p></td><td><p>14/08/2017</p></td><td><p>22/02/2019</p></td><td><p>Bristol-Myers Squibb International Corporation</p></td><td><p>Closed to Recruitment, In Follow Up</p></td></tr><tr><td><p>A PHASE 2 CLINICAL STUDY OF POMALIDOMIDE (CC-4047) MONOTHERAPY FOR CHILDREN AND YOUNG ADULTS WITH RECURRENT OR PROGRESSIVE PRIMARY BRAIN TUMORS</p></td><td><p>17/10/2017</p></td><td><p>27/09/2018</p></td><td><p>CELGENE CORPORATION</p></td><td><p>Closed to Recruitment, In Follow Up</p></td></tr><tr><td><p>A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling</p></td><td><p>15/02/2023</p></td><td><p>31/01/2025</p></td><td><p>Blueprint Medicines Corporation</p></td><td><p>Suspended</p></td></tr><tr><td><p>***</p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td></tr><tr><td><p>***</p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td></tr></tbody></table><p> </p><p>*** Please note that the 2 commercial studies, due to the commercial sensitivity, cannot be shared more widely or made public.</p><p> </p><p>NIHR provides infrastructure support to studies taking place in the National Health Service. For example, staff, research nurses, local networks and NHS trusts will work across many studies, to varying degrees. As a result, NIHR cannot provide precise information on expenditure.</p><p> </p><p>The NIHR Clinical Research Network supports the delivery of high-quality research across the NHS, community and social care and public health organisations. It does this by meeting the costs of additional staff, facilities, equipment and support services.</p><p> </p><p>In May 2018 the Government announced £40 million for brain tumour research as part of the Tessa Jowell Brain Cancer Mission. The Government is committed to funding high-quality brain cancer research. The £40 million funding remains available.</p> answering member printed Lord Markham grouped question UIN HL67 question first answered 13/11/2023 11:45:36 answering member 4948 label Biography information for Lord Markham
tabling member	4230 label Biography information for Baroness Randerson